Targeting of the RAS pathway has long been a critical therapeutic challenge in oncology. Burgess et al. examine how the relative expression of mutant and wild-type KRAS modulates clonal fitness and sensitivity to MEK inhibitors in a model of Kras G12D mutant acute myeloid leukemia and propose its use as a predictive biomarker.
Decades of research on Ras biology have highlighted the central role of this family of small GTPases in human malignancies (reviewed in Karnoub and Weinberg, 2008 and Stephen et al., 2014) . Ras proteins transmit signals from cell surface receptors and activate downstream signaling cascades, including the RAF-MEK-ERK and PI3K-AKT pathways, to regulate cell growth, differentiation, survival, motility, and adhesion. Despite tremendous interest, most strategies employed to target RAS have had less efficacy than hoped in clinical trials, due in part to a complex web of alternative pathways and feedback loops. In this issue of Cell, Burgess and colleagues demonstrate that murine leukemia cells bearing homozygous Kras G12D mutations have a clonal advantage relative to cells with an additional wild-type (WT) Kras allele, and a striking sensitivity to MEK inhibitors (Burgess et al., 2017) .
Mutations that activate RAS signaling, such as mutations in RAS genes (NRAS, KRAS, or HRAS) or RAS regulators (NF1, PTPN11, or CBL), are among the most common genetic abnormalities in cancer. More than 30% of patients with acute myeloid leukemia (AML) bear such mutations, with NRAS and PTPN11 mutations occurring more commonly than KRAS mutations (Papaemmanuil et al., 2016) . While oncogene mutations are traditionally considered to be dominant, with heterozygous lesions driving malignant transformation, some oncogenes have genetic amplification of the mutant allele, deletion of the WT allele, or uniparental disomy resulting in homozygosity for the oncogenic mutation. For example, mutant oncogenes including RAS and EGFR undergo focal amplification (Beroukhim et al., 2010) , and JAK2 mutations are frequently associated with uniparental disomy (Wang et al., 2014) . Recurrence of such genomic events suggests that they confer a clonal advantage to a cell. In addition, alterations in the ratio of mutant to WT oncogene alleles may influence response to therapy.
Burgess and colleagues tested the sensitivity of Kras
G12D
-driven mouse models of AML to MEK inhibition. Among the four models studied, all generated using retroviral insertional mutagenesis followed by a conditional hematopoieticspecific knock-in of Kras G12D , one model, AML101, showed increased sensitivity to the MEK inhibitor PD0325901 (PD901). In search of the causative link for this enhanced therapeutic response and subsequent evolution of PD901 resistance in this model, the authors performed a suite of analyses in samples pre-and post-PD901 treatment. These studies demonstrated duplication of the Kras G12D allele and a loss of WT Kras allele in the pretreatment AML101 sample. In leukemia that relapsed following treatment with PD901 (AML101-R), the authors identified trisomy 6 with duplication of mutant Kras and a single copy of WT Kras. FISH analysis revealed the presence of a small pre-existing trisomy 6 subclone in AML101 prior to therapy, which expanded and became dominant at the time of relapse. Short-term in vivo competition studies demonstrated that AML101 had enhanced clonal expansion relative to AML101-R in the absence of drug treatment, while AML101 was particularly sensitive to PD901 (Figure 1 (Bremner and Balmain, 1990) . BarSagi and colleagues demonstrated that decreased expression of WT HRAS or NRAS sensitizes KRAS-mutated cancer cell lines to DNA damaging agents (Grabocka et al., 2014) . In addition, focal mutant KRAS genomic amplifications and elevated KRAS protein expression are associated with sensitivity of cell lines to KRAS-targeted shRNAs (Singh et al., 2009) . The current study complements these findings and stratifies KRASmutated cell lines into MEK inhibitor sensitive and resistant using the relative expression of mutant versus WT KRAS. It is possible that the WT KRAS allele may mediate MEK inhibitor resistance by reactivation of receptor tyrosine kinases and ERK signaling as has been seen in BRAF-mutant tumors treated with RAF inhibitors (Lito et al., 2013) . Future studies will be needed to understand the molecular basis of the tissue specificity in Burgess et al.'s observation, and to test whether the same principle applies to different oncogenic RAS alleles, some of which preferentially activate different downstream effector pathways.
The findings here indicate that the ratio of mutant and WT RAS alleles could be a predictive biomarker for MEK inhibitors. Retrospective analysis of existing datasets from MEK inhibitor trials and carefully designed prospective studies will be critical to address this point. In human AML, the mutant RAS allele frequency tends to be low as the mutations are acquired late in disease ontogeny, complicating the determination of the zygosity of RAS mutations within an individual cell. Rapid advancement of single-cell technologies, including single-cell DNAand RNA-sequencing, could be instrumental in this context. Since RAS mutations are generally acquired late in leukemogenesis, even complete response of a RAS-mutant clone to MEK inhibitor therapy may leave behind highly oncogenic, MEK insensitive ancestral clones. Finally, since oncogenic activation of the RAS pathway may occur through a myriad of different combinations of mutation or copy number alteration of RAS genes and regulators, it will be important to understand whether this observation holds true in cases of RAS activation by NRAS, PTPN11, and NF1, which are more frequently mutated and/ or lost in AML than KRAS.
Studies of genetic predictors of therapeutic response to targeted agents in cancer often focus on associations with particular mutations. The study by Burgess and colleagues illustrates that sensitivity to MEK inhibition is influenced not only by whether a KRAS mutation is present, but also by the precise configuration of mutations in KRAS alleles. Determination of the ratio of mutant and WT oncogene alleles within a single cancer cell may be critical for prediction of response to targeted cancer therapies. 
